Blood products
Executive Summary
IGIV clinical endpoints and efficacy evaluation of oxygen therapeutics as red cell substitutes are among agenda items for FDA's Blood Products Advisory Committee meeting March 16 and 17. The meeting will be held at the Holiday Inn in Silver Spring, Md. at 8 a.m. both days